Institute for Clinical and Economic Review (ICER) Releases Draft Evidence Report on Treatments for Multiple Sclerosis
November 22, 2016
Update: The National MS Society submitted comments on the ICER draft evidence report on December 21, 216. Click here to view the comments.
November 29, 2016 - The Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report
assessing the comparative clinical effectiveness and value of disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis. The report is open to public comment until December 21, 2016, at 5 p.m. ET. All stakeholders are invited to submit formal comments by email to email@example.com
. The National MS Society and the MS Coalition, a group of nine organizations serving people with MS, will submit comments, but individuals may also submit comments. Guidelines for submitting public comments, including formatting specifications, are available on the ICER website
relevant to the review of the MS medications are available, including the scoping document, stakeholder list and research protocol.
ICER will review all comments received and incorporate any necessary changes in the Evidence Report and revised voting questions that will be posted on or about January 26, 2017. All comments will be posted publicly along with the Evidence Report.
ICER assesses the value of medications by considering price, how well a medication works compared to others, quality adjusted life years and other cost-effectiveness factors. Insurers may use ICER recommendations to develop their formularies, therefore these recommendations could potentially improve or limit access to MS medications. A public meeting to review the report will be held in February 2017 in Oakland, CA and sign-ups to testify at that meeting are currently open